WallStreetZenWallStreetZen

NASDAQ: CLGN
Collplant Biotechnologies Ltd Stock

$5.91-0.06 (-1.01%)
Updated Sep 25, 2023
CLGN Price
$5.91
Fair Value Price
$8.60
Market Cap
$67.41M
52 Week Low
$4.27
52 Week High
$13.97
P/E
-9.69x
P/B
1.87x
P/S
8.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.78M
Earnings
-$6.73M
Gross Margin
88.3%
Operating Margin
-60.62%
Profit Margin
-62.4%
Debt to Equity
0.15
Operating Cash Flow
-$14M
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CLGN Overview

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CLGN ($5.91) is undervalued by 31.26% relative to our estimate of its Fair Value price of $8.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CLGN ($5.91) is significantly undervalued by 31.26% relative to our estimate of its Fair Value price of $8.60 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CLGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLGN due diligence checks available for Premium users.

Be the first to know about important CLGN news, forecast changes, insider trades & much more!

CLGN News

Valuation

CLGN fair value

Fair Value of CLGN stock based on Discounted Cash Flow (DCF)
Price
$5.91
Fair Value
$8.60
Undervalued by
31.26%
CLGN ($5.91) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLGN ($5.91) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CLGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.69x
Industry
12.93x
Market
14.28x

CLGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.87x
Industry
5.09x
CLGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CLGN's financial health

Profit margin

Revenue
$10.2M
Net Income
$5.8M
Profit Margin
56.6%
CLGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$41.6M
Liabilities
$5.5M
Debt to equity
0.15
CLGN's short-term assets ($34.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLGN's short-term assets ($34.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.7M
Investing
-$396.0k
Financing
$89.0k
CLGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CLGN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CLGN$67.41M-0.97%-9.69x1.87x
TLSA$67.30M-0.15%-4.39x3.44x
FIXX$67.64M0.00%-0.51x0.57x
KNTE$67.82M+2.86%-0.51x0.34x
AVRO$68.13M+0.66%-11.77x0.56x

Collplant Biotechnologies Stock FAQ

What is Collplant Biotechnologies's quote symbol?

(NASDAQ: CLGN) Collplant Biotechnologies trades on the NASDAQ under the ticker symbol CLGN. Collplant Biotechnologies stock quotes can also be displayed as NASDAQ: CLGN.

If you're new to stock investing, here's how to buy Collplant Biotechnologies stock.

What is the 52 week high and low for Collplant Biotechnologies (NASDAQ: CLGN)?

(NASDAQ: CLGN) Collplant Biotechnologies's 52-week high was $13.97, and its 52-week low was $4.27. It is currently -57.7% from its 52-week high and 38.41% from its 52-week low.

How much is Collplant Biotechnologies stock worth today?

(NASDAQ: CLGN) Collplant Biotechnologies currently has 11,405,394 outstanding shares. With Collplant Biotechnologies stock trading at $5.91 per share, the total value of Collplant Biotechnologies stock (market capitalization) is $67.41M.

Collplant Biotechnologies stock was originally listed at a price of $8.95 in Jan 31, 2018. If you had invested in Collplant Biotechnologies stock at $8.95, your return over the last 5 years would have been -33.97%, for an annualized return of -7.97% (not including any dividends or dividend reinvestments).

How much is Collplant Biotechnologies's stock price per share?

(NASDAQ: CLGN) Collplant Biotechnologies stock price per share is $5.91 today (as of Sep 25, 2023).

What is Collplant Biotechnologies's Market Cap?

(NASDAQ: CLGN) Collplant Biotechnologies's market cap is $67.41M, as of Sep 26, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Collplant Biotechnologies's market cap is calculated by multiplying CLGN's current stock price of $5.91 by CLGN's total outstanding shares of 11,405,394.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.